Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFM13 in Relapsed/Refractory Hodgkin Lymphoma
NCT02321592Phase 2Completed
- Sponsor
- University of Cologne
- Start
- May 2015
- Primary completion
- Nov 2019
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acimtamig in Hodgkin lymphoma (HL) (3 arms), sponsored by University of Cologne. Primary endpoint: Objective Response Rate at 11 weeks. Started May 2015; status: completed.
02
Drugs
acimtamig
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02321592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321592.